The congenital cataract is one of the leading causes of treatable childhood blindness. Existing classification systems for congenital cataracts are primarily utilized for the diagnosis of the disease. However, these systems provide limited information necessary for the evaluation, formulation, and optimization of treatment plans. Furthermore, research on the classification of congenital cataracts still requires exploration to provide additional evidence supporting molecular diagnosis and syndromic disease diagnosis. This paper reviews relevant studies on the classification of congenital cataracts and discusses the prospects for future research in this area.

The congenital cataract is one of the leading causes of treatable childhood blindness. Existing classification systems for congenital cataracts are primarily utilized for the diagnosis of the disease. However, these systems provide limited information necessary for the evaluation, formulation, and optimization of treatment plans. Furthermore, research on the classification of congenital cataracts still requires exploration to provide additional evidence supporting molecular diagnosis and syndromic disease diagnosis. This paper reviews relevant studies on the classification of congenital cataracts and discusses the prospects for future research in this area.

Congenital cataract (CC) is one of the most common causes of pediatric visual impairment. As our understanding of CC's etiology, clinical manifestations, and pathogenic genes deepens,various CC categorization systems based on diferent classifcation criteria have been proposed. Regrettably, the application of the CC category in clinical practice and scientifc research is limited. It is challenging to obtain preciseinformation that could guide the timely treatment decision-making for pediatric cataract patients or predict their prognosis from a specific CC classification. This review aims to discuss the statusquo of CC categorization systems and the potential directions for future research in this field, focusingon categorization principles and scientific application in clinical practice. Additionally, it aims to propose the potential directions for future research in this domain.

Congenital cataract (CC) is one of the most common causes of pediatric visual impairment. As our understanding of CC's etiology, clinical manifestations, and pathogenic genes deepens,various CC categorization systems based on diferent classifcation criteria have been proposed. Regrettably, the application of the CC category in clinical practice and scientifc research is limited. It is challenging to obtain preciseinformation that could guide the timely treatment decision-making for pediatric cataract patients or predict their prognosis from a specific CC classification. This review aims to discuss the statusquo of CC categorization systems and the potential directions for future research in this field, focusingon categorization principles and scientific application in clinical practice. Additionally, it aims to propose the potential directions for future research in this domain.

Objective: Evidence pertaining to the associations between hyperuricemia and diabetic microvascular complications is limited and inconclusive. In this study, we aimed to prospectively investigate the independent associations of hyperuricemia and retinopathy, nephropathy and neuropathy in individuals with type 2 diabetes mellitus (T2DM). Methods: This cohort study enrolled 25,094 participants from UK Biobank with T2DM and without microvascular complications at baseline. Hyperuricemia was defined as serum uric acid (SUA) higher than 420 μmol/L. The incidence of diabetic microvascular complications was identified from hospital inpatient records that were coded according to the International Classification of Diseases (ICD)-10 coding system. Multivariable adjusted Cox proportional hazards regression models were used to calculate adjusted hazard ratios (aHR). Results: Among all participants, 3,844 (15.3%) were classified as having hyperuricemia at baseline. During a median follow-up of 14.0 years, 555 (14.4%) individuals with hyperuricemia developed diabetic microvascular complications, compared with 12.6% of individuals without hyperuricemia (P=0.002). In the multivariable-adjusted model accounted for socioeconomic status, lifestyle factors, physical and biochemical measurements, and medication use, when compared with individuals of T2DM who had a normal SUA level, those with hyperuricemia had an 82.9% higher risk of developing diabetic nephropathy (95%CI: 1.41-2.38, P<0.001), and a 30.2% higher risk of diabetic neuropathy (95%CI: 1.06-1.60, P=0.011). However, the association between hyperuricemia and diabetic retinopathy was not statistically significant (aHR:1.070, 95%CI: 0.94-1.22, P=0.320). Conclusions: Hyperuricemia was independently associated with diabetic nephropathy and neuropathy but not retinopathy in individuals with T2DM. These findings underscore the importance of monitoring SUA level in prevention of certain microvascular complications.

Objective: Evidence pertaining to the associations between hyperuricemia and diabetic microvascular complications is limited and inconclusive. In this study, we aimed to prospectively investigate the independent associations of hyperuricemia and retinopathy, nephropathy and neuropathy in individuals with type 2 diabetes mellitus (T2DM). Methods: This cohort study enrolled 25,094 participants from UK Biobank with T2DM and without microvascular complications at baseline. Hyperuricemia was defined as serum uric acid (SUA) higher than 420 μmol/L. The incidence of diabetic microvascular complications was identified from hospital inpatient records that were coded according to the International Classification of Diseases (ICD)-10 coding system. Multivariable adjusted Cox proportional hazards regression models were used to calculate adjusted hazard ratios (aHR). Results: Among all participants, 3,844 (15.3%) were classified as having hyperuricemia at baseline. During a median follow-up of 14.0 years, 555 (14.4%) individuals with hyperuricemia developed diabetic microvascular complications, compared with 12.6% of individuals without hyperuricemia (P=0.002). In the multivariable-adjusted model accounted for socioeconomic status, lifestyle factors, physical and biochemical measurements, and medication use, when compared with individuals of T2DM who had a normal SUA level, those with hyperuricemia had an 82.9% higher risk of developing diabetic nephropathy (95%CI: 1.41-2.38, P<0.001), and a 30.2% higher risk of diabetic neuropathy (95%CI: 1.06-1.60, P=0.011). However, the association between hyperuricemia and diabetic retinopathy was not statistically significant (aHR:1.070, 95%CI: 0.94-1.22, P=0.320). Conclusions: Hyperuricemia was independently associated with diabetic nephropathy and neuropathy but not retinopathy in individuals with T2DM. These findings underscore the importance of monitoring SUA level in prevention of certain microvascular complications.

Pediatric cataract, a leading cause of blindness in children globally, imposing a significant financial burden on both families and society. The extensive phenotypic heterogeneity of this condition means that the underlying mechanisms remain poorly understood, limiting the development of precise and effective treatments. The advent of omics technologies has provided potent tools for unraveling the pathogenesis of pediatric cataract. By mapping expression profiles across various molecular levels, these omics approaches enhance our understanding of the disease’s etiological mechanisms, aid in the identification of novel biomarkers and key pathways, and offer researchers new insights for the innovative strategies in disease diagnosis and targeted therapies. In this review, we summarize the application of omics approaches in clinical and basic research on pediatric cataract over the past decade, encompassing genomics, transcriptomics, proteomics, and metabolomics. Furthermore, we discuss the current challenges and future prospects of omics analyses in pediatric cataract studies.

Pediatric cataract, a leading cause of blindness in children globally, imposing a significant financial burden on both families and society. The extensive phenotypic heterogeneity of this condition means that the underlying mechanisms remain poorly understood, limiting the development of precise and effective treatments. The advent of omics technologies has provided potent tools for unraveling the pathogenesis of pediatric cataract. By mapping expression profiles across various molecular levels, these omics approaches enhance our understanding of the disease’s etiological mechanisms, aid in the identification of novel biomarkers and key pathways, and offer researchers new insights for the innovative strategies in disease diagnosis and targeted therapies. In this review, we summarize the application of omics approaches in clinical and basic research on pediatric cataract over the past decade, encompassing genomics, transcriptomics, proteomics, and metabolomics. Furthermore, we discuss the current challenges and future prospects of omics analyses in pediatric cataract studies.